News

Categories

March 18, 2026

Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting

March 17, 2026

Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting

March 2, 2026

Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

March 2, 2026

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

February 12, 2026

Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026

January 27, 2026

Zymeworks Announces Participation in Upcoming Investor Conferences

January 12, 2026

Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy

January 11, 2026

Zymeworks Outlines Strategic Priorities and Outlook for 2026

January 6, 2026

Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit

December 2, 2025

Zymeworks Announces Participation in Upcoming Conferences

November 24, 2025

Zymeworks Announces Participation in Upcoming Investor Conferences

November 18, 2025

Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer